

Special Issue

Current Progress in the Clinical Management and Basic Science of Head and Neck Cancer

Message from the Guest Editor

Every year, more than 800,000 patients are newly diagnosed with HNSCC worldwide and 450,000 patients with HNSCC die. Cigarette smoking, alcohol consumption, and viral infections are recognized as they major factors that can cause HNSCC. In addition to surgery and chemoradiotherapy, molecule-targeted therapy and immunotherapy are the main treatment options for HNSCC. As this area of basic and clinical research has rapidly progressed in recent years, it is important that clinicians understand the basic biology of HNSCC so that they are able to choose an appropriate therapy in the upcoming era of personalized medicine. In this Special Issue of *Cancers*, we welcome both original research and reviews regarding clinical advances in the treatment of HNSCC as well as basic research on its carcinogenesis, the tumor microenvironment and microbiome, and antitumor immunity. Reports of clinical experience or case series are also acceptable if they are related to particularly interesting topics within the field.

Guest Editor

Dr. Takumi Kumai

Department Otolaryngol Head & Neck Surg, Asahikawa Med University,
Midorigaoka East 2-1-1-1, Asahikawa 0788510, Japan

Deadline for manuscript submissions

15 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/200670

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)